ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / INAB / insiders
INTS (39) PASG (34) ATYR (46) BCDA (37) ⌘ Pro Terminal β†’

IN8bio Inc. (INAB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.90 -8.04% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.89

IN8bio Inc. (INAB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (34/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE E β€’ RED ALERT Cap $8.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INAB Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.90 (-8.04% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #652 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does INAB compare to INTS and PASG in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INAB?
β–Ό

Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.89 (-1.64%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (34/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
$3 Bull$1 Base$1 Bear
πŸ“¬ FREE INAB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for INAB)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
πŸ” WHY INAB SCORES 34/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
42
Grade D$1.18-3.4% Next Q
Q2 (-2Q)
39
Grade E$1.14-15.8% Next Q
Q3 (-1Q)
37
Grade E$0.96-6.2% Next Q
Current
34
Grade E$0.90-8.7% Hist 90D Ξ±
Trajectory: D (42) β†’ E (34)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a INAB Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While INAB currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.14) and Max Pain ($0.95) forces dealer call-delta covering toward $2.87.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INABβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œINAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

INAB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INAB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INAB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INAB)

  • βœ“Walkthrough of INAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
INAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.10%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.98H $0.98L $0.90C $0.90VOL 47.9K
RES: $1.58SUP: $0.86SMA50: $1.14SMA200: $1.44
$2.01$1.70$1.39$1.08$0.77RES $1.58SUP $0.86$0.902026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ INAB Butterfly Map β†’ + Track INAB β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INAB today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for INAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INAB)

Health Care Rank #652 of 1016 βš”οΈ INTS vs INAB Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (INAB vs. INTS, PASG, ATYR, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IN8bio Inc. (INAB) ranks #652 by composite RQD confidence (34/100, grade E) and #903 by equity capitalization ($8.9M). Within this direct 5-issuer industry benchmark cohort, INAB leads on earnings valuation at N/A trailing P/E, while INAB leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with INAB at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INAB ACTIVE
IN8bio Inc.
E 34/100 β€” β€” -35.0% -8.04% $8.9M Benchmark Subject
INTS
Intensity Therapeutics Inc.
D- 39/100 β€” β€” -35.0% +1.80% $11.1M /ints-vs-inab β†’
PASG
Passage Bio Inc.
E 34/100 β€” β€” -35.0% -1.99% $11.1M /pasg-vs-inab β†’
ATYR
aTyr Pharma Inc.
D 46/100 β€” β€” -35.0% -8.01% $12.4M /atyr-vs-inab β†’
BCDA
BioCardia Inc.
D- 37/100 β€” β€” -35.0% -7.02% $13.0M /bcda-vs-inab β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001740279

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IN8bio Inc. (INAB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$12.7M, and free cash flow of -$12.7M (+47.4% YoY). On the balance sheet, INAB closed FY2025 with $32.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$19.4M -$12.7M -$12.7M $32.3M β€”
FY2024 (FY) 2024-12-31 $0 -$30.4M -$24.1M -$24.1M $20.9M β€”
FY2023 (FY) 2023-12-31 $0 -$30.0M -$23.3M -$23.3M β€” β€”

3. INAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.90 (-8.04% 1D, market cap $8.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #652 in composite RQD confidence.

How does INAB compare to INTS and PASG in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INAB?

Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INAB trading relative to its 50-day, 200-day, and 52-week technical levels?

INAB last traded at $0.90 (-8.04% on volume of 47,936 shares), positioning the stock -21.05% below its 50-day simple moving average ($1.14) and -37.50% below its 200-day simple moving average ($1.44). Across its 52-week range of $0.87 to $2.73, INAB sits at the 1.6% percentile with a 14-day RSI of 36.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.01).

INAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are INAB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INAB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: INAB RQD Cockpit INAB 12M Forecast INAB Earnings & Move INAB Dividends & DRIP INAB Insiders & 13F INAB Whale Options INAB Profit Sankey INAB News & Why
ROARABLE RATING BRIEF β€’ RQD 34/100 (E) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

INAB β€” IN8bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, INAB scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell β€” Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 8/20 (ROIC of -35%, FCF yield of 0%); Whale 13F Flow scores 3/20 (institutional accumulation and options positioning); Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 8/20 (Beta 1.0, sector sensitivity); and Forensic Balance Sheet scores 10/20 (Altman Z 2.5, Piotroski F 3/9, Debt/Equity 0.5).

For a prospective investor, the rating points to a company that is not currently generating cash returns, with negative ROIC and zero FCF yield. Weakest pillars are institutional flow and insider conviction, which suggests limited sponsorship from either source in the data provided. The forensic balance sheet pillar is the strongest of the five, but still scores only half its maximum. Any upside case would need to rest on factors outside the cash-generation and ownership signals captured here, and the source data does not identify those factors. The grade is a framework-based assessment and does not constitute personalized financial advice.

Recent Catalysts & News Wire Analysis

  • Earnings timing: A TradingView item reports a Q3'26 earnings revenue estimate of 0 USD. A separate item states an earnings date of November 5, 2026.
  • Nasdaq listing compliance: A GlobeNewswire item reports an inducement grant under Nasdaq Listing Rule 5635(c)(4).
  • Signal flags: All three news items carry a YELLOW light and a MARKET WIRE impact label.
  • Proprietary signals: Per the Butterfly Supply-Chain Graph, no proprietary signals are present.

Open Questions

  • What is the company's cash and debt position by period, given that these fields are N/A in the SEC financials?
  • What is the basis for the reported Q3'26 revenue estimate of 0 USD, and what drives the expected earnings timing?
  • What are the terms and context of the Nasdaq Rule 5635(c)(4) inducement grant?
  • What are the company's commercial programs, pipeline, or partnerships that could produce future revenue?
  • What is the net share count and dilution history, which the source data does not provide?

INAB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IN8bio Inc. (INAB) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to INAB Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INAB Bull vs. Bear Conversation Board β€” What's Your Call at $0.90?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INAB 🐻 67% BEARISH CONVICTION
1. Pick Your Side on INAB:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.86 (-12.2%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is INAB (E β€’ RQD 34/100) a Buy at $0.98?

Welcome to the INAB (IN8bio Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell β€” Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.79 (-19.4%)
Spot @ $0.98

Pump the brakes on INAB β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INAB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless IN8bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $1.24 (+26.5%)
Spot @ $0.98

INAB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INAB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.98 (52-wk range $0.87 - $2.73), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%